South Korean CrystalGenomics Targets U.S. And Europe For Osteoarthritis Product
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's CrystalGenomics plans to conduct a Phase IIb or Phase III osteoarthritis safety and efficacy study for its next-generation NSAID CG100649, possibly in Asia next year following positive results from its Phase IIa clinical study in 25 European clinical centers in Germany, Hungary and Ukraine
You may also be interested in...
Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate
SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe
Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate
SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe
Bausch & Lomb Collaborates With Galapagos On Ophthalmic Disease Candidates
Eye health company joins long list of pharmaceutical firms partnering with Galapagos in past year.